Found 162 articles for: "infliximab"
A Survey Assessment of US Dermatologists’ Perception of Biosimilars
June 2017 | Volume 16 | Issue 6 | Original Article | 612 | Copyright © June 2017
BACKGROUND: Biologics have transformed the treatment of psoriasis and psoriatic arthritis, but at a significant cost to payers and patients. The introduction of biosimilars into the US market could...
Read MoreThe Current State of Dermatologists’ Familiarity and Perspectives of Biosimilars for the Treatment of Psoriasis: A Global Cross-Sectional Survey
April 2017 | Volume 16 | Issue 4 | Original Article | 336 | Copyright © April 2017
BACKGROUND: Biologic patent expiration, accelerated approval pathways, and business interests of third party payers and the biopharmaceutical industry are driving the development of biosimilars to ...
Read MoreUse of Biologics in Private Practice: Nine Years of Lessons and Learning
March 2017 | Volume 16 | Issue 3 | Original Article | 215 | Copyright © March 2017
Over a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects p...
Read MoreReversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab
February 2017 | Volume 16 | Issue 2 | Case Reports | 177 | Copyright © February 2017
The use of monoclonal antibodies against interleukin (IL)-12 and -23, such as ustekinumab, has considerably reduced the disease burden in many patients with moderate to severe psoriasis. Reversible po...
Read MoreDown-Titration of Infliximab:The Real-Life Use in Psoriatic Patients
December 2016 | Volume 15 | Issue 12 | Editorials | 1584 | Copyright © December 2016
Recently, the down-titration of the anti-tumor necrosis factor (anti-TNF) agents has become common for the patients with a low disease activity, particularly in rheumatology. However, in dermatology, ...
Read MoreEfficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris: a Randomized Phase III Study (PSO-FAST)
December 2015 | Volume 14 | Issue 12 | Original Article | 1468 | Copyright © December 2015
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes.
OBJECTIVE: To compare the ef...
Read MoreAnti-IL-23 Phase II Data for Psoriasis: A Review
October 2015 | Volume 14 | Issue 10 | Original Article | 1093 | Copyright © October 2015
BACKGROUND: Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of psoriasis. Recent evidence suggests that IL-23 serves a more critical rol...
Read MoreTime to Raise the Bar to Psoriasis Area Severity Index 90 and 100
October 2015 | Volume 14 | Issue 10 | Editorials | 1086 | Copyright © October 2015
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 846 | Copyright © August 2015
BACKGROUND/OBJECTIVE: Despite the aging population, few studies have documented the treatment of geriatric psoriasis. The purpose of this study is to compare the efficacy, safety, and prescribing patt...
Read MoreSecukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials
August 2015 | Volume 14 | Issue 8 | Original Article | 821 | Copyright © August 2015
BACKGROUND: Interleukin (IL)-17A is a key cytokine in the pathogenesis of psoriatic disease of the skin and joints. In phase 3 trials, secukinumab, a fully human anti–IL-17A monoclonal antibody,...
Read MoreEssential Truths for the Care and Management of Moderate-to-Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 805 | Copyright © August 2015
Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologics for psoriasis are directed at mor...
Read MoreSafety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
July 2015 | Volume 14 | Issue 7 | Original Article | 706 | Copyright © July 2015
BACKGROUND: Safety surveillance is needed for biologic therapies for psoriasis.
OBJECTIVE: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis t...
Read MoreThe Value of the Black Box Warning in Dermatology
July 2015 | Volume 14 | Issue 7 | Editorials | 660 | Copyright © July 2015
Boxed, or “black box” warnings are issued by the United States Food and Drug Administration (US FDA) as a means to label drugs associated with serious adverse events. However, there is no ...
Read MoreLeprosy Masquerading as Rheumatoid Arthritis
May 2015 | Volume 14 | Issue 5 | Editorials | 448 | Copyright © May 2015
Next-generation Biologics in the Management of Plaque Psoriasis: A Literature Review of IL-17 Inhibition
March 2015 | Volume 14 | Issue 3 | Original Article | 244 | Copyright © March 2015
Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation...
Read MoreOnychomycosis: Epidemiology, Diagnosis, and Treatment in a Changing Landscape
March 2015 | Volume 14 | Issue 3 | Original Article | 223 | Copyright © March 2015
Onychomycosis is an often overlooked and/or undertreated disease. This may be in part due to an under appreciation among both physicians and patients of its impact on quality of life and the potential...
Read MoreClearance of Psoriasis: The Impact of Private Versus Public Insurance
February 2015 | Volume 14 | Issue 2 | Original Article | 119 | Copyright © February 2015
BACKGROUND: Psoriasis treatments and therapeutic response as they relate to private versus public patient insurance in the United States have not yet been reviewed. Improved understanding could clarif...
Read MoreSystematic Review of Vismodegib Toxicity Profile in the Treatment of Advanced Basal Cell Carcinomas Compared to Other Systemic Therapies in Dermatology
June 2014 | Volume 13 | Issue 6 | Original Article | 729 | Copyright © June 2014
Vismodegib is a first-in-class, hedgehog-signal inhibitor that is FDA-approved for use with advanced basal cell carcinomas (BCCs) that cannot be removed by either surgical resection or treated with ra...
Read MoreImmune Response to Pneumococcus and Tetanus Toxoid in Patients With Moderate-to-Severe Psoriasis Following Long-Term Ustekinumab Use
October 2013 | Volume 12 | Issue 10 | Original Article | 1122 | Copyright © October 2013
BACKGROUND: Little is known about the impact of long-term use of immunosuppressive agents on immune response.
OBJECTIVES: Assess the impact of continuous maintenance ustekinumab treatment on pa...
Read MoreCombination Use of Ustekinumab With Other Systemic Therapies: A Retrospective Study in a Tertiary Referral Center
October 2013 | Volume 12 | Issue 10 | Original Article | 1098 | Copyright © October 2013
BACKGROUND: Patients with moderate to severe psoriasis may not respond adequately to single systemic agent and may require combination systemic therapy.
OBJECTIVE: To evaluate the prevalence, i...
Read More